You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Shingrix Logo

Product menu

Woman in pain with shingles rash

IF YOU CAN PREVENT SHINGLES SUFFERING, WHY WOULDN’T YOU?1

Shingles rash on back

Patients ≥50 Years

1 in 3 individuals will get shingles in their lifetime.2,3 Shingles risk increases with age, with a steep increase at the age of 50.4*,5

By helping to prevent shingles, SHINGRIX reduces the risk of shingles-related complications.1

Find out more

Learn more about SHINGRIX

Red virus icon

Addressing age-related decline in immunity.

SHINGRIX – specifically formulated to help address age-related decline in varicella zoster virus specific immunity in adults 50 years of age and older.1,6-9

REVIEW SCIENTIFIC RATIONALE

Red patient icon, 4 patient figures, 1 of the 4 coloured grey

Who can benefit from SHINGRIX?

There is a 1 in 3 lifetime risk of developing shingles.2,3 Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.10,11

View Patient Profiles

Red circular icon, showing greater than 90% efficacy against herpes zoster

How efficacious is SHINGRIX?

SHINGRIX demonstrated >90 % efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.1,8,9

Review Efficacy Data

Red protective shield

SHINGRIX has a clinically acceptable safety and tolerability profile.

The majority of solicited local adverse reactions were mild to moderate based on data from two large, phase 3 clinical studies.8,9

Review Safety Information

*Retrospective, observational cohort study from the USA using administrative claims data from Truven Health MarketScan Research Databases for the period January 1st, 2011 through December 31st 2011.4

References

  1. Shingrix, Summary of Product Characteristics (SPC), available on https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc. Last Accessed: January 2025
  2.  Harpaz R, et al. MMWR Recomm Rep. 2008 June;57(RR-5):1-30. 2. Mar;12 (3):197-210.
  3. Bollaerts K et al. A systematic review of varicella seroprevaience in European countries before universal childhood immunization: deriving incidence from seroprevaience data. Epidemiol. Infect. (2017), 145, 2666-2677.
  4. Johnson BH, Palmer L, Gatwood J, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the United States [supplement]. MBC Infect. Dis. 2014;15:1-5.
  5. Centres for Disease Control and Prevention. Update on Recommendations for Use of Herpes Zoster Vaccine. 2014 August, 63(33); 729-731.
  6. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella- zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32 (15):1745-53.
  7. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1 /2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012 Oct;206 (8):1280-90.
  8. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
  9. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
  10. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13):1338-43.
  11. Crooke, S.N., et al. Immun Ageing. 2019 Sep 13; 16:25.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

SHINGRIX is owned by or licensed to the GSK group of companies.
©2025 GSK group of companies or its licensor.
GlaxoSmithKline Biologicals S.A. Rixensart, Belgium.

PM-IE-SGX-WCNT-220009
Date of preparation: January 2025